Codexis, Inc. (CDXS)

$2.8

+0.04

(+1.45%)▲

Market is closed - opens 7 PM, 19 Apr 2024

Insights on Codexis, Inc.

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 9.27M → 26.56M (in $), with an average increase of 65.1% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -34.90M → -7.19M (in $), with an average increase of 385.4% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 46.7% return, outperforming this stock by 80.4%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 245.1% return, outperforming this stock by 333.4%

Performance

  • $2.71
    $2.88
    $2.80
    downward going graph

    3.21%

    Downside

    Day's Volatility :5.9%

    Upside

    2.78%

    downward going graph
  • $1.45
    $4.91
    $2.80
    downward going graph

    48.21%

    Downside

    52 Weeks Volatility :70.47%

    Upside

    42.97%

    downward going graph

Returns

PeriodCodexis, Inc.Sector (Health Care)Index (Russel 2000)
3 Months
2.99%
-0.7%
0.0%
6 Months
53.33%
6.6%
0.0%
1 Year
-33.65%
3.7%
-1.5%
3 Years
-88.1%
14.0%
-21.8%

Highlights

Market Capitalization
191.9M
Book Value
$1.24
Earnings Per Share (EPS)
-1.12
PEG Ratio
-1.16
Wall Street Target Price
6.57
Profit Margin
-108.69%
Operating Margin TTM
1.06%
Return On Assets TTM
-17.7%
Return On Equity TTM
-65.89%
Revenue TTM
70.1M
Revenue Per Share TTM
1.03
Quarterly Revenue Growth YOY
-12.6%
Gross Profit TTM
20.5M
EBITDA
-49.3M
Diluted Eps TTM
-1.12
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.65
EPS Estimate Next Year
-0.68
EPS Estimate Current Quarter
-0.12
EPS Estimate Next Quarter
-0.19

Analyst Recommendation

Buy
    84%Buy
    15%Hold
    0
    0%Sell
Based on 13 Wall street analysts offering stock ratings for Codexis, Inc.(by analysts ranked 0 to 5 stars)
Based on 13 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
11
11
12
Hold
2
2
2
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 134.64%

Current $2.80
Target $6.57

Company Financials

FY18Y/Y Change
Revenue
60.6M
↑ 21.13%
Net Income
-10.9M
↓ 52.7%
Net Profit Margin
-17.95%
↑ 28.02%
FY19Y/Y Change
Revenue
68.5M
↑ 12.98%
Net Income
-11.9M
↑ 9.72%
Net Profit Margin
-17.43%
↑ 0.52%
FY20Y/Y Change
Revenue
69.1M
↑ 0.87%
Net Income
-24.0M
↑ 101.17%
Net Profit Margin
-34.77%
↓ 17.34%
FY21Y/Y Change
Revenue
104.8M
↑ 51.69%
Net Income
-21.3M
↓ 11.37%
Net Profit Margin
-20.31%
↑ 14.46%
FY22Y/Y Change
Revenue
138.6M
↑ 32.3%
Net Income
-33.6M
↑ 57.86%
Net Profit Margin
-24.24%
↓ 3.93%
FY23Y/Y Change
Revenue
70.1M
↓ 49.39%
Net Income
-76.2M
↑ 126.96%
Net Profit Margin
-108.69%
↓ 84.45%
Q3 FY22Q/Q Change
Revenue
34.5M
↓ 10.25%
Net Income
-10.0M
↑ 278.48%
Net Profit Margin
-28.99%
↓ 22.12%
Q4 FY22Q/Q Change
Revenue
30.4M
↓ 11.88%
Net Income
-12.6M
↑ 26.15%
Net Profit Margin
-41.5%
↓ 12.51%
Q1 FY23Q/Q Change
Revenue
13.0M
↓ 57.26%
Net Income
-22.6M
↑ 79.43%
Net Profit Margin
-174.22%
↓ 132.72%
Q2 FY23Q/Q Change
Revenue
21.3M
↑ 64.25%
Net Income
-11.5M
↓ 49.05%
Net Profit Margin
-54.04%
↑ 120.18%
Q3 FY23Q/Q Change
Revenue
9.3M
↓ 56.49%
Net Income
-34.9M
↑ 202.94%
Net Profit Margin
-376.29%
↓ 322.25%
Q4 FY23Q/Q Change
Revenue
26.6M
↑ 186.31%
Net Income
-7.2M
↓ 79.4%
Net Profit Margin
-27.08%
↑ 349.21%
FY18Y/Y Change
Total Assets
78.3M
↑ 45.98%
Total Liabilities
22.0M
↓ 24.42%
FY19Y/Y Change
Total Assets
149.1M
↑ 90.43%
Total Liabilities
43.6M
↑ 98.19%
FY20Y/Y Change
Total Assets
221.6M
↑ 48.68%
Total Liabilities
51.5M
↑ 18.34%
FY21Y/Y Change
Total Assets
246.4M
↑ 11.16%
Total Liabilities
82.0M
↑ 59.07%
FY22Y/Y Change
Total Assets
250.4M
↑ 1.63%
Total Liabilities
105.6M
↑ 28.79%
FY23Y/Y Change
Total Assets
136.6M
↓ 45.46%
Total Liabilities
49.9M
↓ 52.7%
Q3 FY22Q/Q Change
Total Assets
235.3M
↑ 0.14%
Total Liabilities
81.2M
↑ 7.48%
Q4 FY22Q/Q Change
Total Assets
250.4M
↑ 6.42%
Total Liabilities
105.6M
↑ 30.11%
Q1 FY23Q/Q Change
Total Assets
218.1M
↓ 12.91%
Total Liabilities
92.1M
↓ 12.83%
Q2 FY23Q/Q Change
Total Assets
206.8M
↓ 5.19%
Total Liabilities
82.6M
↓ 10.24%
Q3 FY23Q/Q Change
Total Assets
154.5M
↓ 25.3%
Total Liabilities
62.9M
↓ 23.82%
Q4 FY23Q/Q Change
Total Assets
136.6M
↓ 11.59%
Total Liabilities
49.9M
↓ 20.66%
FY18Y/Y Change
Operating Cash Flow
-14.1M
↑ 60.84%
Investing Cash Flow
-2.8M
↑ 204.63%
Financing Cash Flow
38.6M
↑ 78.15%
FY19Y/Y Change
Operating Cash Flow
-12.6M
↓ 10.88%
Investing Cash Flow
-3.7M
↑ 32.5%
Financing Cash Flow
54.0M
↑ 39.91%
FY20Y/Y Change
Operating Cash Flow
-16.5M
↑ 31.08%
Investing Cash Flow
-5.7M
↑ 56.83%
Financing Cash Flow
80.8M
↑ 49.75%
FY21Y/Y Change
Operating Cash Flow
-14.3M
↓ 13.34%
Investing Cash Flow
-21.4M
↑ 272.69%
Financing Cash Flow
3.8M
↓ 95.34%
FY22Y/Y Change
Operating Cash Flow
11.3M
↓ 179.09%
Investing Cash Flow
-13.6M
↓ 36.62%
Financing Cash Flow
-575.0K
↓ 115.26%
Q3 FY22Q/Q Change
Operating Cash Flow
19.7M
↓ 1004.81%
Investing Cash Flow
-1.3M
↓ 41.04%
Financing Cash Flow
133.0K
↓ 42.92%
Q4 FY22Q/Q Change
Operating Cash Flow
4.9M
↓ 75.08%
Investing Cash Flow
33.0K
↓ 102.52%
Financing Cash Flow
339.0K
↑ 154.89%
Q1 FY23Q/Q Change
Operating Cash Flow
-9.2M
↓ 287.35%
Investing Cash Flow
-3.3M
↓ 10051.52%
Financing Cash Flow
1.4M
↑ 298.82%
Q2 FY23Q/Q Change
Operating Cash Flow
-16.1M
↑ 74.63%
Investing Cash Flow
-1.6M
↓ 52.16%
Financing Cash Flow
6.9M
↑ 412.06%
Q3 FY23Q/Q Change
Operating Cash Flow
-16.3M
↑ 1.34%
Investing Cash Flow
-1.1M
↓ 29.54%
Financing Cash Flow
-108.0K
↓ 101.56%

Technicals Summary

Sell

Neutral

Buy

Codexis, Inc. is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Codexis, Inc.
Codexis, Inc.
-15.08%
53.33%
-33.65%
-88.1%
-85.92%
Moderna, Inc.
Moderna, Inc.
-0.79%
20.27%
-27.48%
-36.11%
359.53%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-6.12%
9.1%
11.53%
80.35%
170.35%
Novo Nordisk A/s
Novo Nordisk A/s
-6.29%
23.82%
46.7%
242.59%
414.69%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-4.44%
6.95%
20.9%
79.35%
133.77%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Codexis, Inc.
Codexis, Inc.
NA
NA
-1.16
-0.65
-0.66
-0.18
NA
1.24
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.22
-0.29
-0.12
NA
36.27
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
25.71
25.71
1.46
45.13
0.16
0.08
NA
242.47
Novo Nordisk A/s
Novo Nordisk A/s
46.58
46.58
2.4
3.33
0.88
0.23
0.01
23.9
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
28.42
28.42
0.53
16.73
0.23
0.13
NA
68.22
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Codexis, Inc.
Codexis, Inc.
Buy
$191.9M
-85.92%
NA
-108.69%
Moderna, Inc.
Moderna, Inc.
Buy
$39.8B
359.53%
24.73
-68.84%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$98.1B
170.35%
25.71
30.14%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$551.2B
414.69%
46.58
36.03%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$101.9B
133.77%
28.42
36.68%

Institutional Holdings

  • Nantahala Capital Management, LLC

    13.07%

  • BlackRock Inc

    10.24%

  • FMR Inc

    6.21%

  • Vanguard Group Inc

    5.87%

  • Baillie Gifford & Co Limited.

    4.86%

  • Opaleye Management Inc

    4.33%

Corporate Announcements

  • Codexis, Inc. Earnings

    Codexis, Inc.’s price-to-earnings ratio stands at None

    Read More

Company Information

codexis, inc. is a leading protein engineering company applying innovative technologies to unlock the power of proteins™. our proprietary codeevolver® technology platform enables the rapid development and production of highly optimized proteins, custom-designed for your application. codexis’ revolutionary approach to protein engineering starts with an understanding of the desired performance specifications and optimizes a protein specifically to fit these requirements. you get precisely the protein you need for the job you want it to do. guided by proprietary artificial intelligence software and advanced high-throughput screening systems, codexis is able to efficiently generate and introduce function-driven mutations to rapidly improve a protein for its target application. since 2002, codexis’ in-house biochemists, biologists and bioinformatics experts have worked closely with our clients to advance the technologies for protein optimization and production, enabling breakthrough develop

Organization
Codexis, Inc.
Employees
174
CEO
Dr. Stephen George Dilly MBBS, Ph.D.
Industry
Process Industries

Discover More

FAQs